Understanding Drug Development Today: Trends, Impact on Neonatal Drug Development Opportunities

Only available as part of a package

This module presents an overview of the contemporary landscape of drug development and its significant impact on neonatal drug development. Dr Christopher-Paul Milne provides insights into how global phenomena, such as the opioid epidemic, and the COVID-19 pandemic, alongside novel therapies for diabetes, weight loss, targeted therapy, and gene therapy, influence the prospects of developing therapies specifically tailored for neonates. Examining the ripple effect of these developments, the module presents how the allocation of research resources may have unintended consequences for development of neonatal therapies. Lessons learned from orphan drugs are presented as relevant to neonatal drug development. Recent trends including, emerging sponsors and emerging markets are presented as prospects for advancing neonatal therapies in context of dire global statistics of mortality in the neonatal period. Dr Milne shares his thoughts on the needs and opportunities for neonatal drug development.

CE Credit Information:

Participants can earn 1 CE and .5 pharmacology credit for viewing the presentation and completing the evaluation.

The National Association of Neonatal Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Dr. Christopher-Paul Milne, DVM, MPH, JD

After studying and practicing veterinary medicine in the Caribbean as well as the mid-West and mid-Atlantic states for 12 years, Dr. Milne attended The John Hopkins University MPH program. Upon graduation he pursued a career in Public Health at the NJ State Department of Health addressing the impacts of pesticides on children. He later attended law school at the University of New Hampshire and after passing his Law Bar exam accepted a job at the Tufts Center for the Study of Drug Development located in Boston at the Medical School. His initial research project was to evaluate the impacts of new laws being proposed to incentivize the development of pediatric labeling and formulations of drugs previously applicable only for use in adults. He spent 20 years in this area of research and advocacy as well as assuming several administrative positions along the way from Associate Director to Director of Research until retiring from Tufts in 2019. Currently, he has just completed several fictional novels based on his encounters with the exotic flora and fauna of the island of Hispaniola in the Caribbean